Clinical trials: Endocrine System Disorder
Diabetes Mellitus
The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects
The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 24 healthy male subjects. Subjects will receive INS068 injection on Day1 and Day8.
- Trial name
- NCT05336071
- Testing
- INS068 injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Objective Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
- Trial name
- NCT05113693
- Testing
- CKD-393, CKD-501, D759, H053
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Ovarian Hyperstimulation Syndrome
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
- Trial name
- NCT00329693
- Testing
- Norprolac
- Where
- 7 sites in Spain
- Volunteers
- 182 people
- Sponsor
- Ferring Pharmaceuticals
Type 2 Diabetes
Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
The study is being conducted to evaluate and compare the pharmacokinetics of HRS-7535 tablets in subjects with moderate renal insufficiency and healthy subjects.
- Trial name
- NCT06132204
- Testing
- HRS-7535 Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hypertension, Vascular Diseases
SPYRAL GEMINI Pilot Study
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with…
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
- Trial name
- SPYRAL GEMINI (NCT06907147)
- Testing
- Multi-Organ Denervation Gemini System
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Vascular
Diabetes, Diabetes Mellitus, Type 2
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type…
- Trial name
- NCT00455858
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Novo Nordisk A/S
Safety, Tolerability
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)
- Conditions
- Safety, Tolerability, GenSci098, Thyroid Eye Disease (TED)
- Trial name
- NCT06569758
- Testing
- GenSci098
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Diabetes Mellitus
An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2
The purpose of this study is to evaluate the effect of alogliptin benzoate (VIPIDIA®) on glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2 (T2DM) at Month 6.
- Trial name
- NCT02756832
- Testing
- Alogliptin Benzoate
- Where
- 53 sites in Russia
- Volunteers
- 1,409 people
- Sponsor
- Takeda
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
This is an investigator initiated randomized, placebo controlled, double blind, superiority, multi-centre clinical trial. The estimated study project period runs over 3-4 years, including pilot phase.
- Trial name
- VAST-A (NCT05139849)
- Testing
- Vasopressin; Methylprednisolone; Hydrocortisone, Sodium chloride
- Where
- 2 sites in Sweden
- Volunteers
- 1,276 people
- Sponsor
- Tiohundra AB
Pancreatic Neoplasms
A Study for Participants With Pancreatic Cancer
The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study.
- Trial name
- NCT00839332
- Testing
- LY2603618, Gemcitabine
- Where
- 30 sites in United States, Germany and 4 more
- Volunteers
- 157 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
- Trial name
- CATT1 (NCT06334133)
- Testing
- Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- vTv Therapeutics
Ovarian Neoplasms
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass
Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine…
- Trial name
- NCT06566716
- Testing
- CleoDX ovarian cancer test
- Where
- 19 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleo Diagnostics Ltd
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.
- Trial name
- NCT02227849
- Testing
- Canagliflozin (TA-7284), GLP-1 analogue
- Where
- 4 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
This trial is conducted in Europe and North America. The aim of the trial is to compare the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated…
- Trial name
- CONCLUDE (NCT03078478)
- Testing
- Insulin degludec, Insulin glargine
- Where
- 229 sites in United States, Canada and 10 more
- Volunteers
- 1,609 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Healthy
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
- Trial name
- NCT01867307
- Testing
- Empagliflozin, BI 10773
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cardiovascular Risk Factors, Hyperlipidemia
European Study of Cardiovascular Risk
The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.
- Conditions
- Cardiovascular Risk Factors, Hyperlipidemia, Hypertension, Diabetes
- Trial name
- EURIKA (NCT00882336)
- Where
- 775 sites in Austria, Belgium and 10 more
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Diabetes
One Touch VerioIQ US Clinical Outcomes Study
Evaluation of the clinical benefits of One Touch VerioIQ system
- Trial name
- NCT01627899
- Testing
- One Touch VerioIQ Blood Glucose Monitor
- Volunteers
- 5 people
- Sponsor
- LifeScan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.